发布求助
文献互助 智能选刊 最新文献

Pharmaceutical patent analyst最新文献

筛选
英文 中文
Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations. 靶向嵌合体（PROTACs）在肿瘤学中的蛋白水解：专利和监管考虑的回顾。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-05-15 DOI: 10.1080/20468954.2025.2500809
Sowndharya M, Ramesh Joga, Kajal Gandhi, Sravani Yerram, Rajeev Singh Raghuvanshi, Saurabh Srivastava
{"title":"Proteolysis targeting chimeras (PROTACs) in oncology: a review of patents and regulatory considerations.","authors":"Sowndharya M, Ramesh Joga, Kajal Gandhi, Sravani Yerram, Rajeev Singh Raghuvanshi, Saurabh Srivastava","doi":"10.1080/20468954.2025.2500809","DOIUrl":"https://doi.org/10.1080/20468954.2025.2500809","url":null,"abstract":"<p><strong>Introduction: </strong>Proteolysis Targeting Chimeras (PROTACs) represents a groundbreaking advancement in drug discovery and targeted protein degradation. Unlike traditional small-molecule inhibitors, PROTACs leverage the cell's natural protein degradation machinery to selectively degrade pathogenic proteins, offering significant therapeutic potential for previously undruggable targets and complex diseases such as cancer and neurodegenerative disorders. Understanding the regulatory landscape governing their approval is crucial as their development accelerates.</p><p><strong>Areas covered: </strong>This review provides an overview of recent patents, regulatory considerations, emerging concerns, and future perspectives of PROTACs in cancer management.</p><p><strong>Expert opinion: </strong>From a regulatory perspective, PROTACs present unique challenges and opportunities. Their dual-functional nature requires a nuanced approach to classification and approval, blending small-molecule and biologic regulatory frameworks. Specific guidelines addressing pharmacokinetic and pharmacodynamic profiles are needed. Comprehensive preclinical evaluation and robust clinical trial designs are essential to manage off-target effects and immunogenic responses. The collaboration between regulatory bodies, academia, and industry is crucial for establishing a clear pathway for PROTAC approval. Future considerations must account for advancements in PROTAC technology to ensure safe and effective therapies reach patients. While PROTACs hold immense promise, their regulatory journey requires tailored guidelines and rigorous evaluation to realize their full potential.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144079546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development in medicinal chemistry via oxadiazole derivatives: patent spotlight 2020-2024. 恶二唑衍生物药物化学的发展：专利焦点2020-2024。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-05-07 DOI: 10.1080/20468954.2025.2500810
Mehwish Solangi, Fouzia Naz, Syed Abid Ali, Khalid Mohammed Khan
{"title":"Development in medicinal chemistry <i>via</i> oxadiazole derivatives: patent spotlight 2020-2024.","authors":"Mehwish Solangi, Fouzia Naz, Syed Abid Ali, Khalid Mohammed Khan","doi":"10.1080/20468954.2025.2500810","DOIUrl":"https://doi.org/10.1080/20468954.2025.2500810","url":null,"abstract":"<p><p>The oxadiazole derivatives are part of the azole family and have drawn significant interest in medicinal chemistry due to their wide range of biological activities and promising pharmacological profiles. This patent spotlight highlights the developments of the oxadiazole-based compounds reported between 2020 and 2024, with applications in treating diseases such as cancer, bacterial infections, metabolic disorders, and neurodegenerative conditions. These compounds act through various mechanisms, including enzyme inhibition, receptor modulation, and disruption of microbial and cancer cell pathways. Their structural flexibility allows for the design of novel molecules targeting specific therapeutic areas. The spotlight on these recent patents underscores oxadiazole derivatives' growing importance in drug discovery, offering potential advancements in efficacy and safety for future therapeutic agents.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-10"},"PeriodicalIF":1.8,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144038055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent spotlight on theranostics targeting fibroblast activation protein for personalized cancer care. 针对成纤维细胞活化蛋白的个体化癌症治疗的专利聚光灯。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-05-06 DOI: 10.1080/20468954.2025.2500811
Jason A Witek, Allen F Brooks, Benjamin L Viglianti, Peter J H Scott
{"title":"Patent spotlight on theranostics targeting fibroblast activation protein for personalized cancer care.","authors":"Jason A Witek, Allen F Brooks, Benjamin L Viglianti, Peter J H Scott","doi":"10.1080/20468954.2025.2500811","DOIUrl":"https://doi.org/10.1080/20468954.2025.2500811","url":null,"abstract":"<p><p>Theranostics represents the state-of-the-art in precision oncology treatment, and is gaining momentum because of the potential to help improve outcomes for even late-stage cancer patients. Pairs of identical (or very similar) molecules are labeled with both diagnostic and therapeutic radionuclides, and used to both image and treat cancer. The FDA approval and commercialization of theranostics for neuroendocrine tumors and prostate cancer has spurred development of new theranostics as well as significant venture and pharma investment, such that both academic medical centers and companies are working to advance the field. One theranostic target of interest is the Fibroblast Activation Protein (FAP) because its expression in many different tumor types offers potential for a pan-cancer theranostic. In this <i>Patent Spotlight</i>, we present the first analysis of patents issued for FAP-targeting radiopharmaceuticals, providing perspective on current trends and challenges as well as future directions.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-13"},"PeriodicalIF":1.8,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144006214","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights June - July 2024. 专利亮点2024年6月- 7月。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-03-07 DOI: 10.1080/20468954.2025.2459586
Hermann A M Mucke
{"title":"Patent highlights June - July 2024.","authors":"Hermann A M Mucke","doi":"10.1080/20468954.2025.2459586","DOIUrl":"https://doi.org/10.1080/20468954.2025.2459586","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-5"},"PeriodicalIF":1.8,"publicationDate":"2025-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143573190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PLGA and cancer: a comprehensive patent-based review on the present state of art. PLGA与癌症：基于专利的综合综述。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-03-01 DOI: 10.1080/20468954.2025.2470103
Venessa Nath, Mohini Singh, Bani Kumar Jana, Tumpa Sarkar, Niva Rani Gogoi, Bhaskar Mazumder
{"title":"PLGA and cancer: a comprehensive patent-based review on the present state of art.","authors":"Venessa Nath, Mohini Singh, Bani Kumar Jana, Tumpa Sarkar, Niva Rani Gogoi, Bhaskar Mazumder","doi":"10.1080/20468954.2025.2470103","DOIUrl":"https://doi.org/10.1080/20468954.2025.2470103","url":null,"abstract":"<p><p>Poly (lactic-co-glycolic acid) (PLGA) is a highly efficient biodegradable polymeric nanoparticle (NP). Owing to its low toxicity, controlled and sustained release qualities, and biocompatibility with tissue and cells, the US FDA has approved its usage in drug delivery systems. The manufacturing and characterization techniques, surface changes, encapsulation of anticancer medicines, active or passive tumor targeting, and various PLGA nanoparticle release methods have been explored in the research arena in the past decade and patents have been filed across the globe. This review covers nanotechnology-backed PLGA patent literature for various types of cancers available on distinguished and eminent patent databases like 'Espacenet' and 'Patent Scope' ranging within a time frame from 2008 to 2024. This review is the first ever reported compilation of the state-of-the-art patent-based literature in PLGA nanoparticles. This review will pave a path for researchers of the present era and future, to understand the research landscape in PLGA nanoparticles and cancer therapy and pave a path for further connective research in the arena of PLGA-based nanoparticles and cancer formulation development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-15"},"PeriodicalIF":1.8,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143531750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Developments in research and commercialization of PI3K and AKT targets: a patent-based landscape. PI3K和AKT靶点的研究和商业化进展：基于专利的前景。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-02-24 DOI: 10.1080/20468954.2025.2470102
Hai-Long Zhang, Zhaochen Lin, Ying Zhang
{"title":"Developments in research and commercialization of PI3K and AKT targets: a patent-based landscape.","authors":"Hai-Long Zhang, Zhaochen Lin, Ying Zhang","doi":"10.1080/20468954.2025.2470102","DOIUrl":"https://doi.org/10.1080/20468954.2025.2470102","url":null,"abstract":"<p><p>PI3K and AKT signaling pathway has been linked to the pathophysiology of various diseases. This pathway has emerged as a crucial therapeutic strategy for cancer and other diseases. To better understand recent development of PI3K and AKT, a patent-based landscape study was performed. The results shows that both PI3K and AKT targets have shown prolific patent filings over the past 20 years. This study is the first to depict the therapeutic applications of both PI3K and AKT targets based on a patent big data analysis. Ten key therapeutic applications were identified, with over 77% of patents related to anti-cancer therapy for both PI3K and AKT targets. Additionally, our findings show that combination therapy is a distinguishing feature for drugs targeting both PI3K and AKT. The average time from patent application to drug approval for PI3K target drugs is 8.8 years. PI3K target drugs obtain market approval faster compared to AKT drugs. Approximately, 2 years of patent term extension could be obtained if the time from the patent application date to the drug approval date is less than 10 years.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-8"},"PeriodicalIF":1.8,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs. 美国专利局关于双重专利的相互矛盾的裁决危及仿制药和生物仿制药。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-02-08 DOI: 10.1080/20468954.2025.2459582
Sarfaraz K Niazi
{"title":"Contradicting rulings of the US patent office on double patenting jeopardize the generic and biosimilar drugs.","authors":"Sarfaraz K Niazi","doi":"10.1080/20468954.2025.2459582","DOIUrl":"https://doi.org/10.1080/20468954.2025.2459582","url":null,"abstract":"<p><p>Obviousness-type double patenting is allowed only in the US, but only if a terminal disclaimer and the same ownership are made for the expiry of the patent. Historically, this provision has hampered the entry of generic and biosimilar drugs due to the legal complexity and cost burden of resolving patent thickets accumulated by the originator companies. The United States Patent and Trademark Office (USPTO) proposed a change in the ruling in March 2024 to avoid double patenting if the patent to which it is tied in terminal disclaimer has any claims that have been invalidated as anticipated or obvious. This rule change aimed to promote innovation and competition by deterring strategies that leverage multiple patents for obvious variants to obstruct competitors. However, after receiving 349 comments on the proposed rule change, the USPTO withdrew its plan in December 2024 despite most comments favoring it. In a contrary move, the USPTO secured a court ruling that the terminal disclaimers do not apply to extended patent expiry due to the failure of the USPTO to prosecute a patent on a timely basis. The double patenting must end to enable more affordable generic and biosimilar drugs.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-9"},"PeriodicalIF":1.8,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From supplements to superbugs: how probiotic patent gaps drive antimicrobial resistance and the CRISPR-Cas solutions. 从补充剂到超级细菌：益生菌专利差距如何推动抗菌素耐药性和CRISPR-Cas解决方案。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-02-05 DOI: 10.1080/20468954.2025.2459592
Absar Talat, Asad U Khan
{"title":"From supplements to superbugs: how probiotic patent gaps drive antimicrobial resistance and the CRISPR-Cas solutions.","authors":"Absar Talat, Asad U Khan","doi":"10.1080/20468954.2025.2459592","DOIUrl":"https://doi.org/10.1080/20468954.2025.2459592","url":null,"abstract":"","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-3"},"PeriodicalIF":1.8,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Emerging patents versus brain eating amoebae, Naegleria fowleri. 新兴专利与吃脑变形虫，福氏奈格里亚。
IF 1.8
Pharmaceutical patent analyst Pub Date : 2025-02-03 DOI: 10.1080/20468954.2025.2459584
Ruqaiyyah Siddiqui, David Lloyd, Naveed Ahmed Khan
{"title":"Emerging patents versus brain eating amoebae, <i>Naegleria fowleri</i>.","authors":"Ruqaiyyah Siddiqui, David Lloyd, Naveed Ahmed Khan","doi":"10.1080/20468954.2025.2459584","DOIUrl":"https://doi.org/10.1080/20468954.2025.2459584","url":null,"abstract":"<p><p>Primary Amoebic Meningoencephalitis (PAM) is a severe and often fatal infection caused by the free-living amoebae <i>Naegleria fowleri</i>. This condition typically results from exposure to contaminated warm freshwater/inadequately treated recreational water/or ablution/nasal irrigation with contaminated water. The management of PAM is hindered by the absence of effective treatment coupled with challenges in early diagnosis. This review explores emerging patents that could be utilized for the treatment, diagnosis of PAM, as well as water treatment. Recent patents from the past five years, along with research and innovations are reviewed and categorized into therapeutic agents, water treatment technologies, and diagnostic methods. It is hoped that collaboration and awareness between pharmaceutical companies, water industries, and academic institutions is essential for advancing effective strategies against this severe central nervous system pathogen.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":"1-6"},"PeriodicalIF":1.8,"publicationDate":"2025-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143123413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patent highlights August-September 2023. 2023 年 8 月至 9 月的专利要点。
IF 1.3
Pharmaceutical patent analyst Pub Date : 2024-03-18 DOI: 10.4155/ppa-2023-0039
Hermann Am Mucke
{"title":"Patent highlights August-September 2023.","authors":"Hermann Am Mucke","doi":"10.4155/ppa-2023-0039","DOIUrl":"https://doi.org/10.4155/ppa-2023-0039","url":null,"abstract":"<p><p>A snapshot of noteworthy recent developments in the patent literature of relevance to pharmaceutical and medical research and development.</p>","PeriodicalId":20011,"journal":{"name":"Pharmaceutical patent analyst","volume":" ","pages":""},"PeriodicalIF":1.3,"publicationDate":"2024-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140144000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信